PRACTICE PATTERNS OF RADIOTHERAPY IN CERVIX CANCER AMONG MEMBER GROUPS OF THE GYNECOLOGIC CANCER INTERGROUP (GCIG) D GAFFNEY 1, A DU BOIS 2, K NARAYAN.

Slides:



Advertisements
Similar presentations
Eric Pujade-Lauraine Hôpitaux Universitaires Paris Centre Site Hôtel-Dieu, Paris, France Ve spolupráci je síla.
Advertisements

Post-operative Radiotherapy for Esophageal Cancer Parag Sanghvi, M.D., M.S.P.H. Department of Radiation Medicine Esophageal Care Conference 3/26/2007.
Please note, these are the actual video-recorded proceedings from the live CME event and may include the use of trade names and other raw, unedited content.
Upfront Surgery vs Neoadjuvant Chemotherapy Patients closed / 550 Leading EORTC Participating NCIC CTG Presentated at IGCS 2008 EORTC
Early Stage NSCLC: The Role of Chemotherapy Eric Vallieres, MD.
GCIG Prague 2010 On behalf of the Gynecologic Cancer Intergroup (GCIG) 4 th Ovarian Cancer Consensus Conference Co-Chairs Gavin CE Stuart & Henry C Kitchener,
Controversies in Adjuvant Therapy for Pancreatic Cancer Parag Sanghvi M.D. Tasha McDonald M.D. Department of Radiation Medicine OHSU.
FIFA WORLD CUP ALGERIA Africa ARGENTINA / South America.
Morbidity / Complications
IMRT vs. BRACHYTHERAPY FOR SOFT TISSUE SARCOMA. EXTERNAL RT IN STS NCI Trial (Yang JC et al, JCO 1998) Extremity / Superficial Trunk STS (n=141) LSS Alone.
Impact of imaging on newer radiation techniques in Gynaecological cancer.
NCI Workshop on Advanced Technologies in Radiation Oncology: Cervix December 1, 2006 David Gaffney MDPhD Huntsman Cancer Hospital University of Utah.
SERVICES TRADE RESTRICTIVENESS INDEX PROFESSIONAL SERVICES ARCHITECTURE Russell V. Keune Architect, USA.
GCIG Cervix Committee: Prague 2010 William Small Jr. Satoru Sagae.
Cervical Cancer. Cervix Lower part of the uterus Lower part of the uterus Connects the body of the uterus to the vagina (birth canal) Connects the body.
GCIG Meeting 29th May 2009 The Implications of Primary Chemotherapy for Clinical Trials Iain McNeish Professor of Gynaecological Oncology Barts and the.
Dr. Rico Liu Consultant, Department of Clinical Oncology, Queen Mary Hospital Honorary Clinical Associate Professor, Department of Clinical Oncology, The.
CET Cancer Center Oakland California High Dose Rate (HDR) Brachytherapy Gynecological Cancer D. Jeffrey Demanes M.D
IMRT for the Treatment of Anal Cancer Kristen O’Donnell, MS3 December 12, 2007.
Impact of overall treatment time and dose escalation on local control in locally advanced cervical cancer treated by chemo-radiation and image-guided adaptive.
ACRIN Abdominal Committee ACRIN Gynecologic Committee Fall Meeting 2010 Susanna I Lee, MD, PhD, Chair Massachusetts General Hospital.
Study proposal After 4 A Phase III intergroup trial on adjuvant therapy in radically operated endometrial cancer patients (FIGO stage IC-IIIC) with high.
R System. Lymphadenectomy pelvic para-aortic no Lymphadenectomy epithelial invasive ovarian cancer FIGO IIB - IV ECOG 0/1 and no CI against LNE no visible.
Management of Endometrial Cancer in 2008 Marcus E. Randall, MD, FACR Chair and Professor Markey Foundation Endowed Chair Department of Radiation Medicine.
Are there benefits from chemotherapy to early endometrial cancer
Phase II Trial of Continuous Course Re- irradiation Concurrent with Weekly Cisplatinum and Cetuximab for Recurrent Squamous Cell Carcinoma of The Head.
Clinico-Dosimetric Correlation for Acute and Chronic Gastrointestinal Toxicity in Patients of Locally Advanced Carcinoma Cervix Treated With Conventional.
Quantitative Dosimetric Analysis Of Patterns Of Local Relapse After IMRT For Primary Extremity Soft Tissue Sarcomas Ryan M. Lanning, Sean L. Berry, Michael.
Radiation Therapy in the Management of Cervical Carcinoma Patrick S Swift, MD Medical Director, Radiation Oncology Alta Bates Comprehensive Cancer Center.
CR07 results and informed patient consent David Sebag-Montefiore Leeds Cancer Centre.
Louise E. Francis, B.S., CMD. Gynecologic Oncology Group (GOG) The only National Cancer Institute funded cooperative group in the US currently conducting.
Mahatma Gandhi Cancer Hospital and Research Institute Dr P. S. Bhattacharyya, MD Radiation Oncologist. Elekta Synergy CT Simulator Flexitron HDR.
THE OUTBACK TRIAL A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared.
Robert Taylor MD, PhD, Alexander Whitley MD, PhD, Craig Baden MD, Javier Lopez-Araujo MD, Sui Shen PhD, O. Lee Burnett MD, Jennifer De Los Santos MD and.
Local recurrence after rectal cancer resection is strongly related to the plane of surgical (PoS) dissection and is further reduced by pre-operative short.
Endometrial Committee David Scott Miller, M.D., F.A.C.O.G., F.A.C.S. Director and Dallas Foundation Chair in Gynecologic Oncology Professor of Obstetrics.
LET’S TALK ABOUT COUNTRIES AND CAPITAL CITIES Look, repeat and memorize.
An international education opportunity.
Endometrial Cancer Commitee Minutes Prague, 21 October 2010 David Miller, Ketta Lorusso.
COUNTRIES WHERE ARE YOU FROM?.
Adjuvant treatment for endometrial cancer Ameri A Associate Professor of Radiation Oncology Shahid Beheshti University of Medical Sciences Dec Pars.
Risk Factors and Incidence of Fistula formation in salvage laryngectomy Miss Lisa Pitkin Consultant ENT Head and Neck Surgeon.
Preliminary Results of the MRC CR07 / NCIC CO16 Randomized Trial Short course pre-op vs selective post-op chemo-RT for rectal cancer Local Recurrence after.
Outcome of patients treated with Image Guided Brachytherapy for Locally Advanced Carcinoma of the Cervix at Royal Devon & Exeter Hospital Dr.
Endometrial Cancer Commitee Minutes Chicago June 3, 2010 David Miller, Ketta Lorusso.
T. Hijal MD, A. Al Hamad MD, N. Khalaf, K. Sultanem MD, S. Faria MD and T. Muanza MD McGill University, Department of Radiation Oncology, Montréal, Québec,
GCIG trials for rare ovarian histologies Edward L. Trimble, MD, MPH National Cancer Institute, USA.
To investigate the acute toxicity of 3D conformal concurrent chemo RT (Keeping PTV Dmax
Results Increased median PFS 2.8 months No apparent increased survival. HR=0.985 CR+PR=46% Gemzar vs 36% control Independently Assessed Increased toxicity,
PURPOSE PURPOSE METHODSMETHODS CONCLUSIONSCONCLUSIONS Long-term results of daily HDR brachytherapy in the postoperative setting of endometrial carcinoma.
Taipei VGH Practice Guidelines: Oncology Guidelines Index Cancer of Cervix Version Table of Content StagingStaging, Manuscript Taipei Veterans General.
USD billion
Taipei Veterans General Hospital Practices Guidelines Oncology Cervical Cancer Version VGH Survival Data as of YYYY/MM/DD Proofing on 2010/MM/DD.
RCR Bladder Cancer Radiotherapy Audit 2016
Gynecological Treatment Planning
THREE OR FOUR FRACTIONS PER WEEK IN POSTOPERATIVE HIGH DOSE RATE BRACHYTHERAPY (HDRBT) FOR ENDOMETRIAL CARCINOMA (EC). Rovirosa A1, Vargas M1, Ascaso C2,
Feasibility of hippocampal sparing radiation therapy for glioblastoma using helical Tomotherapy Dr Kamalram THIPPU JAYAPRAKASH1,2,3, Dr Raj JENA1,4 and.
นายแพทย์ธราธร ตุงคะสมิต นายแพทย์ชำนาญการพิเศษ โรงพยาบาลมะเร็งอุดรธานี
IMRT delivery of preoperative, high dose radiotherapy to a large volume, with Simultaneous Integrated Boost (SIB) in retroperitoneal sarcomas: The Ottawa.
The Most Visited Countries
Comparative Results of Vaginal Relapses and Toxicity of Three 192-Ir HDR brachytherapy (BT) Schedules in Postoperative Endometrial Carcinoma (EC). Rovirosa.
Dr Gemma Eminowicz Consultant Clinical Oncologist, UCLH, London
RTOG 0126 A Phase III Randomized Study of High Dose 3D-CRT/IMRT versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer Bijoy.
What is the most appropriate therapy for a 50 year old patient with T3N+ rectal cancer and isolated resectable liver metastases?
Systemic chemotherapy->chemoradiation->surgery.
PRESENTATOR: MD VƯƠNG NHẤT PHƯƠNG. HO CHI MINH CITY ONCOLOGY HOSPITAL
New developments in oncological treatment for Stage 3 NSCLC
Management of endometrial cancer found on routine hysterectomy for benign disease Prof Dr M Anıl Onan MAY ANTALYA.
2006 Rank Adjusted for Purchasing Power
IMagyn050 YO39523/GOG-3015/ENGOT-ov39 Recruitment Update
Proton Therapy for Thymic Malignancies: Multi-institutional Patterns-of-Care and Early Clinical Outcomes from the Proton Collaborative Group Registry &
Presentation transcript:

PRACTICE PATTERNS OF RADIOTHERAPY IN CERVIX CANCER AMONG MEMBER GROUPS OF THE GYNECOLOGIC CANCER INTERGROUP (GCIG) D GAFFNEY 1, A DU BOIS 2, K NARAYAN 3, N REED 4, T TOITA 5, S PIGNATA 6, P BLAKE 7, L PORTELANCE 8, A SADOYZE 9, R POTTER 10, A COLOMBO 11, M RANDALL 12, MR MIRZA 13, EL TRIMBLE 14, 1 RTOG, USA 2 AGO-OVAR, Germany 3 ANZGOG, Australia/New Zealand 4 EORTC, Scotland 5 JGOG, Japan 6 MITO, Italy 7 Royal Marsden Hospital, England 8 NCIC, Canada 9 SGCTG, Scotland 10 AGO-AUST, Austria 11 MANGO, Italy 12 GOG, USA 13 NSGO, Scandinavia 14 NCI, USA

RTOG USA JGOG Japan MITO Italy EORTC ANZGOG Australia/New Zealand AGO-OVAR Germany MRC (NRCI) NCIC CanadaAGO-AUST Austria SGCTG Scotland MANGO Italy NSGO Scandinavia GEICO Spain GINECO France GOG USA

Methods Survey Developed Radiotherapy practice –Indications –Doses –Fields –Chemotherapy –Brachytherapy 4 questionnaires per group 39 returned from 13 groups Descriptive statistics

RT Doses Gy / / / / / /- 5.1

Total Point A Doses: North America Compared to Other Cooperative Groups Gy p=0.103

Type of Simulation for Definitive RT

Size of Pelvic Field for Definitive RT N=34

IMRT in Definitive RT? N=27

Type of Chemotherapy for Definitive RT? N=37

Dosing of CDDP for Definitive RT (n=30)

Adjuvant Chemo post Hysterectomy and Concurrent ChemoRT N=34

Intervene for a low Hemoglobin 31 N=33

Type of Brachytherapy for Definitive RT 25 N=29

Indications for Para-aortic RT

Upper Border for Para-aortic RT N=31

Vaginal Brachytherapy post Hysterectomy 18 Rx’d to ½ cm, 8 to Vag surface, 1 to one cm 23/25 recorded dose to bladder and rectum 23/27 used HDR For HDR –Median dose: 17.5 Gy –Median dpf: 6 Gy Degree of Vagina Treated

Conclusions Radiotherapy Practices among members of GCIG are similar in terms of doses and fields Concomitant chemotherapy is used by all groups with CDDP predominating There is no consensus on vaginal brachytherapy prescription Radiotherapy practices should not be a barrier to intergroup participation in clinical trials

Acknowledgments Mason Schoenfeldt and Monica Bacon Executive Board of the GCIG Respondents Collegiality among all members